MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways ; volume:24 ; number:1 ; day:10 ; month:3 ; year:2024 ; pages:1-32 ; date:12.2024
Cancer cell international ; 24, Heft 1 (10.3.2024), 1-32, 12.2024
- Urheber
-
Zabeti Touchaei, Arefeh
Vahidi, Sogand
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03293-6
- URN
-
urn:nbn:de:101:1-2405122113329.238914100890
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zabeti Touchaei, Arefeh
- Vahidi, Sogand
- SpringerLink (Online service)
Ähnliche Objekte (12)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer